Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer

por prodriguez | Ene 1, 2022 | Publicaciones - CIMO-01

Bote, H; Mesas, A; Baena, J; Herrera, M; Paz-Ares, L – 2022

Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports

por prodriguez | Ene 1, 2022 | Publicaciones - CIMO-01

Rocha-de-Lossada, C; Linero, CA; Ortega, AS; Calvo-de-Mora, MR; Rachwani, R; Borroni, D; Alba, E; Orgaz, MB; Romano, V – 2022

Validation of pain catastrophizing scale on breast cancer survivor.

por prodriguez | Ene 1, 2022 | Publicaciones - CIMO-01

Perez-Cruzado, D; Roldan-Jimenez, C; Iglesias-Campos, M; Pajares, B; Alba, E; Cuesta-Vargas, A – 2022

Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer

por prodriguez | Ene 1, 2022 | Publicaciones - CIMO-01

Baena-Canada, Jose M.; Gamez-Casado, Salvador; Rodriguez-Perez, Lourdes; Bandera-Lopez, Cristina; Mesas-Ruiz, Andres; Campini-Bermejo, Alicia; Bernal-Gomez, Marta; Zalabardo-Aguilar, Manuel; Calvete-Candenas, Julio; Martinez-Bernal, Gala; Quilez-Cutillas, Alicia;...

Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction

por prodriguez | Ene 1, 2022 | Publicaciones - CIMO-01

Oliver, J; Garcia-Aranda, M; Chaves, P; Alba, E; Cobo-Dols, M; Onieva, JL; Barrgan, I – 2022

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

por prodriguez | Ene 1, 2022 | Publicaciones - CIMO-01

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Csoszi, T; Anton, A; Turner, N; Casas, MI; Morales, S; Alba, E; Calvo, L; De La Haba-Rodriguez, J; Ramos, M; Murillo, L; Santaballa, A; Alonso-Romero, JL;...